PR88557

PORTSMOUTH, N.H., March 18, 2021 /PRNewswire=KYODO JBN/ --

Epredia, a global leader in precision cancer diagnostics, and Paige, a global

leader in AI-based diagnostic software in pathology, have announced today that

they have entered into a commercial distribution agreement for Paige's

comprehensive portfolio of diagnostic software solutions.

Under the terms of this agreement, Epredia has been appointed as a global

distribution partner of the entire Paige portfolio of imaging diagnostic

solutions. In addition, Epredia will have exclusive distribution rights in

Japan. In the second quarter of 2021, Epredia will begin to commercialize the

Paige solutions alongside existing Epredia products in the United States and

major European Countries, further strengthening its comprehensive digital

pathology portfolio that already includes the best-in-class CE-marked 3DHistech

P1000 scanner*.

The Paige portfolio includes the Paige Platform, a comprehensive imaging

solution comprised of a fast, zero-footprint viewer, storage capabilities and

AI-based diagnostic software to help pathologists review cases and support

their overall workflow.

The FDA-cleared and CE-marked Paige Platform features FullFocus(TM), an

intuitive and responsive viewer for pathology scans that supports primary

diagnosis and their Data Management solution for storage of pathology scans.

The Paige Platform is designed to be compatible with existing pathology

solutions, including most scanners, monitors, and laboratory information

systems.

Paige's AI-based diagnostic software solutions are designed to increase the

number of cases that can be reviewed and with greater confidence and accuracy.

Currently Paige Prostate and Paige Breast are CE-marked and available for

clinical use outside of the United States. Paige Prostate RUO and Paige Breast

RUO are research-use only solutions that are available in the United States.

"We are extremely excited to be entering into this partnership with Paige to

commercialize their highly innovative portfolio of AI-based digital pathology

solutions," explained John Marotta, President, Epredia and Chief Executive

Officer, PHC Holdings Corporation. "We believe that digital pathology is a key

part of cancer diagnostics of the future that can greatly improve patient care.

We see enormous potential in the Paige portfolio and believe it perfectly

complements our existing portfolio. This deal gives us access to a highly

innovative portfolio of products that can enable us to deliver on our mission

of improving lives by enhancing cancer diagnostics for patients."

"This commercial partnership with Epredia is an exciting step for Paige and we

are thrilled to be working with one of the leading companies in anatomical

pathology. Epredia's extensive global commercial reach will support our efforts

to expand our geographical footprint," said Leo Grady, Ph.D., Chief Executive

Officer of Paige. "Our aim is to transform the diagnostics space by offering a

portfolio of software applications that help optimize patient outcomes by

enabling pathologists to unlock insights from each sample and return results to

the clinician and patient more quickly. This commercial agreement will help

deliver our solution into the hands of more pathologists across the world to

help patients get the most timely and effective care."

* Regulatory requirements for the 3DHistech P1000 scanner vary by country,

please consult with your commercial partner to confirm the approved use of the

scanner in your country.

Notes for Editors

About Epredia

Epredia is a global leader in the anatomical pathology field, providing

comprehensive solutions for precision cancer diagnostics and tissue

diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser,

Microm, Shandon, and Richard-Allan Scientific, Epredia's portfolio includes

microscope slides, instruments and consumables. Epredia was established

following the acquisition of Thermo Fisher Scientific's Anatomical Pathology

business by PHC Holdings in 2019. Epredia has major sites in the United States,

the United Kingdom, Germany, Switzerland and China with a total of around 1,200

employees. Epredia is committed to achieving its mission to improve lives by

enhancing cancer diagnostics for patients around the world. For further

information on Epredia and its products, please visit www.epredia.com.

About Paige

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial

Sloan Kettering Cancer Center (MSK). The company builds computational pathology

products designed so patients and their care teams can make effective, more

informed treatment decisions. With this new class of AI-based technologies

positioned to drive the future of diagnostics, Paige created a platform to

deliver this novel technology to pathologists to transform their workflow and

increase diagnostic confidence and productivity. Paige's products deliver

insights to pathologists and oncologists so they can arrive efficiently at more

precise diagnoses for patients. Paige is the first company to receive FDA

breakthrough designation for computational pathology products.

For additional information, please visit: https://www.paige.ai,

https://www.paigeplatform.com, Twitter [https://twitter.com/paige_ai], and

LinkedIn [https://www.linkedin.com/company/paige-ai/].

Photo - https://mma.prnewswire.com/media/1458464/Epredia.jpg

Logo - https://mma.prnewswire.com/media/1458465/Epredia_Logo.jpg

Source: Epredia